Procognia (Israel) Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Procognia (Israel) Ltd
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.
Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.
Astex Technology's takeover of Schering AG spin-out metaGen Pharmaceuticals provides the Cambridge-based firm with more cash, a stronger relationship with a pharmaceutical partner, complementary technology assets, and, potentially, an improved preclinical pipeline. MetaGen investors inch closer to an exit by trading stakes in an early-stage, unfloatable company for a piece of a more mature, well-funded firm several steps closer to an IPO.
- Research, Analytical Equipment & Supplies
Drug Discovery Tools
- Drug Discovery Tools